SCANCELL HOLDINGS PLC – Iscib1 Mhra Cta Approval For Ph3 Trial
RNS Number : 2225R Scancell Holdings Plc 19 August 2026 19 August, 2026 Scancell Holdings plc Scancell Receives
RNS Number : 2225R Scancell Holdings Plc 19 August 2026 19 August, 2026 Scancell Holdings plc Scancell Receives
RNS Number : 6489O Scancell Holdings Plc 31 July 2026 31 July 2026 Scancell Holdings plc (“Scancell” or the
A Private Investor is a recipient of the Information who meets all of the conditions set out below, the recipient:
A Private Investor is a recipient of the Information who meets all of the conditions set out below, the recipient:
Scancell, the developer of novel immunotherapies for the treatment of cancer, announces its interim results for the six months ended 31 October 2019.
Scancell, the developer of novel immunotherapies for the treatment of cancer, today announces a business update following the progress made in H1 2019.
Scancell, the developer of novel immunotherapies for the treatment of cancer, announces that, further to the Company’s announcement on 13 June 2019, Martin Diggle, Co-Founder and Portfolio Manager of Vulpes Investment Management, has been appointed to the Company’s Board of Directors as a Non-Executive Director with immediate effect.
Scancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, are pleased to provide an update on their clinical development partnership* for the development of Scancell’s ImmunoBody® vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC).
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has received all of the UK regulatory, ethical and legal approvals required to initiate the Phase 2 clinical trial to assess the safety and efficacy of SCIB1 in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda). The UK arm of the study is therefore expected to start during the second quarter of this year, as planned.
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that the Japanese Patent Office has granted a patent that provides protection for Scancell’s Moditope® immunotherapy platform.